 SPARTA, N.J., March 11, 2021 GLOBE NEWSWIRE -- PLx Pharma Inc. NASDAQ: PLXP PLx or the Company, a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuardTM drug delivery platform to provide more effective and safer products, with its lead products VAZALORETM 325 mg and VAZALORETM 81 mg referred to together as VAZALORE, announced today that Natasha Giordano, President and Chief Executive Officer, and Rita OConnor, Chief Financial Officer, will present at the Oppenheimer 31st Annual Healthcare Conference as follows: 